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ABSTRACI'
We investigated the effects of the antiviral agent distamycin A and of a distamycin
derivative (FCE 24517) which possesses antineoplastic activity on the binding of some
regulatory proteins to DNA. Both compounds inhibited the binding to DNA of the ubiquitous
octamer binding factor OTF 1 and of the erythroid specific GATAAG protein ( NFE 1). This
was shown using the electrophoretic mobility shift assay on a DNA fragment of human y-globin
gene promoter (-156 to -201), on the same fragment with a point mutation (T to C mutation)
known to have an increased affinity of binding for NFE 1, on a DNA fragment of human
histone H2B promoter and on a DNA fragment of mouse al globin promoter. The ability of
distamycin or of FCE 24517 to inhibit the binding was specific for AT-rich sequences since
neither drug inhibited the binding of nuclear protein factors to the sequence CCACACCC of the
human B globin gene. Binding to DNA was investigated by evaluating the drugs' ability to
protect selected sequences from DNase I digestion (DNase footprinting). Distamycins binding
was highly preferential for DNA sequences containing stretches of AT. These studies indicate
that chemicals which have a high degree ofDNA sequence-specific binding can selectively
inhibit the binding of regulatory proteins to DNA. These effects might be responsible for
modification of the transcripion of specific genes and might to some extent account for these
drugs' antiviral and antineoplastic activities. This approach offers potential for the investigation
of new such drugs.
INTRODUCTUIN
Distamycin A is an antibiotic originally isolated from Streptomyces distallicus (1) and
subsequently obtained by total synthesis (2). It has strong antiviral activity (3). Recently some
distamycin derivatives proved to be potent antiproliferative agents with activity against some
murine tumors (4,5) , but their mechanism of action is still unknown. They form a strong
reversible complex with double helical B-DNA with high selectivity for AT rich sequences.
Distamycin A binds deeply into the minor groove of B-DNA ; NH groups of each of the
three pyrrolecarboxamide rings form hydrogen bonds with N-3 of adenine or 0-2 of thymine
and the CHs of the aromatic pyrroles are bound to the C-2 hydrogens of adenines by Van der
Waals interaction (6) . Distamycin A binding to DNA widens the minor groove by several
Angstroms by bending the DNA helix and by inducing conformational changes in neighboring
DNA (6). These changes can alter the chromatin structure (7,8) and consequently affect normal
DNA-protein interactions.
It is widely accepted that transcriptional initiation is mediated by formation of stable
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complexes between DNA binding proteins (trans factors) and sequences (cis elements) in
promoter and enhancer regions. These elements contain short regulatory boxes that mediate
DNA-protein interaction, leading to transcriptional activation (9). By exploiting the gel shift
assay and DNase I footprinting techniques, several sequence specific DNA binding proteins
have been identified (10). The octanucleotide ATlTGCAT sequence has been shown to be
important in trancriptional activation of several genes including human histone H2B,
immunoglobin, U2 and Ul small nuclear RNA, and binds a ubiquitous (OTF 1) and a lymphoid
specific (OTF 2) protein (11-13); mutations of every single nucleotide (with the possible
exception of the first A) greatly impair binding of both proteins. Another conserved sequence
(GATAAG) in promoters and enhancers of several globin genes binds a protein (NFE 1)
present only in erythroid cells ( 13,14).
Since distamycin A and its derivatives bind to DNA containing AT sequences, these drugs
might alter the binding of protein factors to boxes in which AT sequences are essential for
recognition and stable binding, thus possibly interfering with the activation of several genes.
This study was undertaken to verify this hypothesis.
Distamycin A and its derivative N-deformyl-N- (4-(N,N-bis-(2-chloroethyl)
amino)benzoyl) - distamycin A (FCE 24517) were synthetized by Farmitalia-Carlo Erba, Milan,
Italy and dissolved in water or 0.1% DMSO respectively for DNA or cell treatment.
DNAfrget
Sequences ofDNA fragments used in these experiments were as follow (only top strand is
shown): human y-globin: from -156 to -201 (CCCTGGCAAAGTCTGTCTATAAACGTAACT
CTATCACACCCCTTCC) (13,14) -175 mutant y-globin: same as above except T to C
mutation at -175;
H2B promoter: from -68 to -23 (CTGAAGTTGAGAAGTGGAATAAACGTATTCG
CTAAGATATATIC)
mouse al globin promoter: (CGGGCAACTGATAAGGATCCC) (14).
All fragments were 32p labeled at 5' ends with T4 polynucleotide kinase and [ y 32P] ATP
according to standard procedures.
Nuclear extracts.
Nuclear extracts from human erythroleukemia cells (K562) were prepared according to
Dignam et al. (15).
DNA fragments labeled at the 5'-end (0.1-0.5 ng) were preincubated for 30 min at room
emperature with different concentrations of Distamycin A or FCE 24517 in the presence of poly
(dI-dC) (2 jg) and then incubated with nuclear extracts (5 gg of proteins) for other 30 min,
electrophoresed in 50mM Tris borate pH 8.2 and autoradiographed (16).
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Figure 1
Binding of nuclear factors to human y-globin fragment. Labeled DNA was preincubated with 50
(lanes 1,2,3) or 250 jiM (lanes 4,5,6) distamycin A (D) or with 50 (lanes 8,9,10) or 250 jM
(lanes 11,12,13) FCE 24517 (F) for 30 min and then incubated for 30 min with K562 nuclear
extracts as indicated in the figure. Lane 7 is untreated DNA.
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Figure 2
A) Effect of distamycins on NFE 1 binding to -175 fragment; the -175 fragment was
preincubated with 10 (lane 1) 25 (lane 2) 50 (lane 3) 100 (lane 4) and 200 jM (lane 5)
Distamycin A (D) or with 10 (lane 7) 25 (lane8) 50 (lane 9) 100 (lane 10) and 200 gM (lane 11)
FCE 24517 (F) for 30 min before addition of K562 nuclear extract (5jg). Lane 6 is untreated
fragment plus nuclear extract.
B) Effect of distamycins on NFE 1 binding to mouse al globin fragment.
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Figure 3
Effect of distainycins on OTF 1 binding to an oligonucleotide derived from the sequence of H2B
promoter (from -68 to -23); pretreatment of DNA fragments with distamycins and subsequent
treatmnent with K562 nuclear extract were as described in figure 2.
DNase I footrinting (17)
The top strand of each oligonucleotide was 5'-end labeled with polynucleotide kinase and
[y2P] ATP, before annealing with the bottom strand. The double stranded fragment
oligonucleotdde was then incubated with the drug (see above) for 30 min and treated with DNase
I (0.01 units) for 5 min at room temperature. The reaction was stopped by adding tRNA (15
gg), ammonium acetate (final concentration 2.5M) and ethanol. After precipitation DNA was
resuspended in loading buffer and electrophoresed on 20% acrylamide-7M urea gels and
autoradiographed.
Using the electrophoretic mobility shift assay the 32P labeled BstNI-Apa I fragment
(from -201 to -156) of the y-globin gene promoter had been shown to bind two proteins
present in nuclear extracts from K562 cells (12). These proteins have been characterized in
terms of their DNA binding specificity and correspond to the ubiquitous octamer binding
protein (OT'F 1) (11,12,16) and to the erythroid-specific GATAAG protein (NFE 1) (14,18 and
references within). Preincubation of the labeled fragment with distamycin A and FCE 24517
clearly lowered the intensity of both these bands (Fig.1) . This effect was already observed at
50 giM distamycin A or FCE 24517 and increased at higher drug concentrations (compare
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Figure 4
Effect of distamycins on nuclear factors binding to a human B-globin fragment; the BstNI-Hind
III B-globin fragment was incubated with 200 (lane 1) 100 (lane2) 50 (lane 3) 25 (lane 4) or 10
FM (lane 5) Distamycin A (D) or with 200 (lane 7) 100 (lane 8) 50 (lane 9) 25 (lane 10) and
FM (lanel 1) FCE 25417 (F) for 30 min followed by incubation with K562 nuclear extract for
30 min. Lane 6 is DNA incubated with nuclear extract only.
for example lane 7 with lanes 2,5,9 and 12). Preincubation of the drug with DNA is essential
for this effect; when the drug was added together with DNA and protein or preincubated with
protein alone, little or no effect was observed (data not shown).
In order to investigate the effect of these drugs on the binding of the two proteins
separately, we used a DNA fragment containing a point mutation in the octamer sequence ( -175
T to C) ; this mutation, abolishes the binding of OTF 1 and enhances that of NFE 1 (12). As
shown in Fig. 2 A the binding ofNFE 1 was severely affected by both compounds at 50 .M but
a significant reduction was already seen at lower concentrations, particularly in the case of FCE
24517. These results were confirmed by employing a different oligonucleotide (14) derived
from mouse a globin promoter and showing a high affinity binding site for NFE 1
(GATAAG), as the only homology with the previous one (Fig.2B) .
Using an octa box containing synthetic oligonucleotide derived from human histone H2B
promoter (11) and shown to bind OTF 1, a single specific retarded band was generated.
Treatment with distamycin A or FCE 24517 prevented protein binding in a concentration
dependent manner from 25 to 200 tM (Fig. 3).
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Figure 5
DNase I footprinting ofDNA fragments treated with distamycins:
(A) Human y -globin fragment (5'-end labeled on the top strand) was treated with 50 (lane 2)
or 250 ±M (lane 1) FCE 24517 (F) or with 50 (lane 4) or 250 jM (lane 5) distamycin A (D)
for 30 min and then subjected to cleavage by DNase I. Lane 3 is the untreated control; A+G is
the Maxam-Gilbert sequencing reactions. The protected sequence is indicated; the octamer is
boxed. (B) Oligonucleotide derived from sequence of human H2B promoter treated with 10
(lane 2) 25 (lane 3) 50 (lane 4) 100 jM (lane 5) FCE24517 (F) for 30 min before addition of
DNase I. Lane 1 is the untreated control. The sequence of the protected regions is indicated and
the octamer is boxed. (C) -175 mutant y-globin fragment. Treatments and lanes are the same as
in panel B.
(D) The sequence (from -201 to -156) of human y-globin gene is illustrated. The octamer(binding site of OTF 1) is indicated in bold type ; on the bottom strand the GA(T,C)AGA
sequences (binding site of NFE 1) are underlined; the region protected as in panel A is marked
with a zigzag above it.
In order to verify whether the ability of distamycin A and FCE 24517 to inhibit protein
binding was specific for AT-containing DNA boxes, we investigated the effect of the two
drugs on the binding of nuclear proteins to a previously characterized human B- globin CACCC
box containing fragment Hindm -BstNI (see ref. 19). Incubation of this fragment with nuclear
extracts from K562 cells generated several retarded bands (B1-B4) shown by DNase I footprint
and methylation interference experiments to interact with the CCACACCC sequence (19); they
therefore do not require AT stretches for specific recognition. Fig. 4 shows that neither
1056
Nucleic Acids Research
distamycin A nor FCE 24517 had any detectable effect on binding to this DNA box even at very
high concentrations (200 IM).
To establish the precise site of binding of distamycin A and FCE 24517 on the
oligonucleotides we investigated these drugs' ability to protect selected sequences from
DNase I digestion (DNase I footprinting) (17). When the normal globin fragment was
employed, both compounds protected a sequence spanning the octa box from DNase I
digestion (Fig. 5A). Similar results were also obtained employing the y-globin mutated fragment
and the H2B oligonucleotide (Fig. SC and SB). In both cases GC rich sequences were not
protected (see -190/-200 region in y-globin fragment fig. SA and SC) and the corresponding
bands were even enhanced. Significant protection was already evident at low drug
concentrations (10-25 gM). In the case of the H2B oligonucleotide a second protection was
observed in another stretch of AT present in this fragment (-30/-20), corresponding to the
histone H2B TATA box (11).
DISCUSSION
The antibiotic distamycin A has potent antiviral activity (3) and some of its derivatives
inhibit proliferation of certain murine tumors (4,5). The mechanisms of action of these
compounds have still to be elucidated.
The specific binding of distamycin to AT-rich sequences has been already described (2,6)
and the chemical basis for this interaction has been well characterized. However, to our
knowledge the influence of distamycins interactions with DNA on the binding of regulatory
proteins to DNA has not yet been investigated. To this aim we used as a model system two
different sequences known to be important in gene regulation. The ATGCAAAT octamer is
essential for transcriptional regulation of several ubiquitously or tissue-specifically expressed
genes (for a review see refs 9,11,12,16) transcribed by either pol II or pol III (20); additionally,
it has been implicated in the stimulation ofDNA replication by NF 1I (21,22) . The GATAAG
sequence is present in promoter and enhancer elements of several globin genes, and is affected
by mutations up-regulating y-globin expression in adult erythroid cells (14,18).
We found that distamycin A or its derivative FCE 24517 inhibited the binding of specific
nuclear proteins to the ATGCAAAT and GATAAG sequences. The effect of the drugs appears
to be selective for these sequences, as indicated by the following observations:
- the drugs have no effect on protein binding to the C-rich CCACACCC sequence (Fig 4);
-footprinting experiments show that the drugs interact preferentially with the AT rich region
including the ATGCAAAT motif (Fig 5), an effect that is particularly clear at low drug
concentrations; that the octamer is a preferred target is also shown by the fact that the drugs
inhibit the binding of nuclear proteins to this motif irrespective of the flanking sequences (see for
example the octa motif in the H2B histone and globin genes respectively). As regards the NFE
1 binding site, the footprint shown in fig 5 indicates that the sequence AGAT(G/A) (-171 to
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- 175) reacted with the drug; this sequence is known, from methylation interference experiments
and from the effects of the -175 mutation on binding (14), to be an important part of the NFE 1
recognition motif;
-the drug's effect is not due to interaction with nuclear protein itself, as indicated by
preincubation experiments and by its inability to inhibit the binding of nuclear proteins
interacting with other motifs (CCACACCC box, fig 4).
Considering that some distamycin derivatives, including FCE 24517, have recently shown
potent antineoplastic activity (4,5) our results invite the speculation that these compounds might
act by preventing the DNA-binding of specific regulatory proteins, thus inhibiting the
transcription of genes which are important for neoplastic cell growth . This would be a novel
mode of action for an anticancer agent. Indeed, recent results (unpublished) by this laboratory
show that in L1210 mouse leukemia cells these compounds lower (by more than 90%) the level
of histone H2B mRNA (whose transcription is dependent on the octa motif) but not that of
histone H4 and actin mRNAs.
ACKNOWLEWMENTS
This work was partially supported by CNR Grants No 87.00866.51 Progetto Finalizzato
Ingegneria genetica e Basi Molecolari delle malattie ereditarie and Progetto Finalizzato
Biotecnologie e Strumentazione to S.O., by CNR Grants No 86.00653.44 Progetto Finalizzato
Oncologia and Progetto Finalizzato Biotecnologie e Strumentazione to M.D. and by Grants from
the Italian Association for Cancer Research (AIRC) to S.O. and M.D.. R.M. is supported by a
fellowship from AIRC.
*To whom correspondence should be addressed
REFERENCES
1. Di Marco, A., Gaetani, M., Orezzi, P., Scotti, T. and Arcamone, F. (1962) Cancer
Chemother. Rep. 18, 15-19.
2. Arcamone, F., Penco, S., Nicolella, V., Orezzi P., and Pirelli, A.M. (1964) Nature 203,
'1064-1065.
3. Casazza, A.M., Fioretti, A., Ghione, M., Soldati, M. and Verini, M.A. (1965) Antimicrob.
Ag. Chemother. 5, 593-598.
4. Giuliani, F.C., Barbieri, B., Biasoli, L., Geroni, C., Menozzi, M. and Mongelli, N. (1988)
Proc. Am. Ass. Cancer Res. 29, 330.
5. Barbieri, B., Giuliani, F.C., Pezzoni, G., Lazzari, E., Arcamone, F. and Mongelli, N. (1988)
Proc. Am. Ass. Cancer Res. 29, 330.
6. Kopka, M.L., Yoon, C., Goodsell, D., Pjura, P. and Dickerson, R.E. (1985) Proc. natn.
Acad. Sci. USA 82. 1376-1380.
7. Low, C.M.L., Drew, H.R. and Waring M.J. (1986) Nucleic Acids Research 14,6785-6801.
8. Portugal, J. and Waring, M.J. (1987) Nucleic Acids Research 15, 885-903.
9. Maniatis, T., Goodboum, S. and Fischer, J.A. (1987) Science 236, 1237-1244.
10. Wingender E. (1988) Nucleic Acids Research 16, 1879-1902.
1058
Nucleic Acids Research
11. Sive, H.L. and Roeder, R.G. (1986) Proc. natn. Acad. Sci. USA 83, 6382-6386.
12. Staudt, L.M., Singh, H., Sen, R., Wirth, T., Sharp, P.A. and Baltimore, D. (1986)
Nature 323, 640-643.
13. Mantovani, R., Malgaretti, N., Giglioni, B., Comi, P., Cappellini, N., Nicolis, S. and
Ottolenghi, S. (1987) Nucleic Acids Research 15, 9349-9364.
14. Mantovani, R., Malgaretti, N., Nicolis, S., Ronchi, A., Giglioni, B. and Ottolenghi, S.
Nucleic Acids Research, 16, 7783-7797.
15. Dignam, J.D., Lebovitz, R.M. and Roeder R.G. (1983) Nucleic Acids Research 11,
1475-1489.
16. Singh, H., Sen, R., Baltimore, D. and Sharp, P.A. (1986) Nature 319, 154-158.
17. Schmitz, A. and Galas, D.J. (1979) Nucleic Acids Research 6, 111-137
18. Superti-Furga, G., Barberis, A., Schaffner, G. and Busslinger, M. EMBO Journal, in press.
19. Mantovani, R., Malgaretti, N., Nicolis, S., Giglioni, B., Comi, P., Cappellini, N., Bertero,
M.T., Caligaris-Cappio, F. and Ottolenghi, S. (1988) Nucleic Acids Research 16,
4299-4313.
20. Carbon, P., Murgo, S., Ebel, J-P., Krol, A., Tebb, G., Mattaj, I.W. (1987) Cell 51, 71-79.
21. DePamphilis, M.L. (1988) Cell 52, 635-638.
22. Pruijn, G.J.M., van Driel, W., van Miltenburg, R.T. and van der Vliet, P.C. (1987) EMBO
Joumal 6, 3771-3778.
1059
